ES2928084T3 - Inhibidores de GDF-8 - Google Patents

Inhibidores de GDF-8 Download PDF

Info

Publication number
ES2928084T3
ES2928084T3 ES16711043T ES16711043T ES2928084T3 ES 2928084 T3 ES2928084 T3 ES 2928084T3 ES 16711043 T ES16711043 T ES 16711043T ES 16711043 T ES16711043 T ES 16711043T ES 2928084 T3 ES2928084 T3 ES 2928084T3
Authority
ES
Spain
Prior art keywords
bipyridin
alkyl
pyridine
imidazo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16711043T
Other languages
English (en)
Spanish (es)
Inventor
Pingyu Ding
Marina Gelman
Todd Kinsella
Rajinder Singh
Somasekhar Bhamidipati
Upender Velaparthi
Robert Borzilleri
Hasibur Rahaman
Jayakumar Warrier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Rigel Pharmaceuticals Inc
Original Assignee
Bristol Myers Squibb Co
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Rigel Pharmaceuticals Inc filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2928084T3 publication Critical patent/ES2928084T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES16711043T 2015-02-20 2016-02-15 Inhibidores de GDF-8 Active ES2928084T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119052P 2015-02-20 2015-02-20
PCT/US2016/017938 WO2016133838A1 (en) 2015-02-20 2016-02-15 Gdf-8 inhibitors

Publications (1)

Publication Number Publication Date
ES2928084T3 true ES2928084T3 (es) 2022-11-15

Family

ID=55587333

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16711043T Active ES2928084T3 (es) 2015-02-20 2016-02-15 Inhibidores de GDF-8

Country Status (8)

Country Link
US (1) US9981944B2 (cg-RX-API-DMAC7.html)
EP (1) EP3259264B1 (cg-RX-API-DMAC7.html)
JP (1) JP6800158B2 (cg-RX-API-DMAC7.html)
CN (1) CN107531666A (cg-RX-API-DMAC7.html)
AR (1) AR103740A1 (cg-RX-API-DMAC7.html)
ES (1) ES2928084T3 (cg-RX-API-DMAC7.html)
TW (1) TW201643157A (cg-RX-API-DMAC7.html)
WO (1) WO2016133838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE50634E1 (en) 2014-01-24 2025-10-14 Turning Point Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
RU2732405C2 (ru) 2015-07-02 2020-09-16 Тёрнинг Поинт Терапьютикс, Инк. Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ
LT3319969T (lt) 2015-07-06 2024-06-10 Turning Point Therapeutics, Inc. Diarilo makrociklo polimorfas
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN108431008A (zh) * 2015-11-19 2018-08-21 蓝图药品公司 可用于治疗与ntrk相关的病症的化合物和组合物
JP6756925B2 (ja) 2017-01-11 2020-09-16 ロダン・セラピューティクス，インコーポレーテッド ヒストンデアセチラーゼの二環式阻害剤
SMT202200232T1 (it) 2017-08-07 2022-07-21 Alkermes Inc Inibitori biciclici di istone deacetilasi
KR102600330B1 (ko) 2017-08-22 2023-11-10 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로시클렌 유도체
CN110066276B (zh) 2018-01-24 2020-09-18 上海璎黎药业有限公司 芳香杂环化合物、其中间体、制备方法、药物组合物和应用
AU2019360941B2 (en) * 2018-10-15 2025-02-27 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
AR119140A1 (es) 2019-06-13 2021-11-24 Pi Industries Ltd Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043781A2 (en) 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
JP2001097950A (ja) * 1999-10-01 2001-04-10 Sankio Chemical Co Ltd 新規なピリジン誘導体
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
NZ547794A (en) 2003-12-18 2009-11-27 Janssen Pharmaceutica Nv Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
FR2925902B1 (fr) 2008-01-02 2011-01-07 Sanofi Aventis DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2010009469A2 (en) 2008-07-18 2010-01-21 Peckerar Martin C Thin flexible rechargeable electrochemical energy cell and method of fabrication
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US8575203B2 (en) 2010-04-21 2013-11-05 Boehringer Ingelheim International Gmbh Chemical compounds
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
CA2804285C (en) * 2010-07-05 2019-05-14 Merck Patent Gmbh Bipyridyl derivatives useful for the treatment of kinase - induced diseases
CN104394869A (zh) 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
CN104093716B (zh) 2011-10-31 2017-06-23 克赛农制药股份有限公司 联芳醚磺酰胺化合物及其作为治疗剂的用途
CN104379574B (zh) 2012-05-15 2017-03-01 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
SG11201502527UA (en) 2012-10-05 2015-04-29 Rigel Pharmaceuticals Inc Gdf-8 inhibitors
TW201422606A (zh) 2012-11-08 2014-06-16 必治妥美雅史谷比公司 可作爲激酶調節劑之經雙環雜環取代之吡啶化合物
CN105120862A (zh) 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
WO2015044172A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
ES2713323T3 (es) 2013-10-11 2019-05-21 Hoffmann La Roche Compuestos de sulfonamida heterocíclicos sustituidos útiles como moduladores de trpa1
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3129367B1 (en) 2014-04-08 2019-09-04 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors

Also Published As

Publication number Publication date
US9981944B2 (en) 2018-05-29
JP2018505903A (ja) 2018-03-01
JP6800158B2 (ja) 2020-12-16
TW201643157A (zh) 2016-12-16
US20160264553A1 (en) 2016-09-15
CN107531666A (zh) 2018-01-02
EP3259264A1 (en) 2017-12-27
EP3259264B1 (en) 2022-07-27
WO2016133838A1 (en) 2016-08-25
AR103740A1 (es) 2017-05-31

Similar Documents

Publication Publication Date Title
ES2928084T3 (es) Inhibidores de GDF-8
ES2789331T3 (es) Inhibidores de TGF-beta
KR102793183B1 (ko) 헤테로시클릭 rip1 키나제 억제제
EP3283479B1 (en) Tgf-beta inhibitors
ES2759240T3 (es) Compuestos de piridina 2,3-disustituidos como inhibidores de TGF-beta
ES2895626T3 (es) Derivados de imidazol condensados como inhibidores de TGF-beta
ES2918924T3 (es) Inhibidores de TGF-beta
ES2813875T3 (es) Compuestos y procedimientos de uso
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
CN103012399B (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
JP2018150319A (ja) キナーゼ阻害剤としてのビアリールアミド化合物
KR20230090318A (ko) 헬리오스의 피페리디닐 소분자 분해 및 사용 방법들
AU2017208555B2 (en) New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors
CN105732614B (zh) 磺酰胺基芳基炔类化合物及其用途
ES2844211T3 (es) Compuestos y composiciones en calidad de inhibidores de quinasa
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
KR20150090044A (ko) 아자퀴나졸린 카복사미드 유도체
WO2019189555A1 (ja) 複素環化合物
CN110156782B (zh) 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物
EP3810596B1 (en) Quinoline derivatives useful as tyrosine kinase inhibitors
TW202039425A (zh) 雙取代炔類衍生物、包含其之藥物組成及組、及用於製備其之製程
CN115772167A (zh) 含脲结构的化合物及其应用
HK40001081A (en) Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
HK1244785B (en) Tgf-beta inhibitors